During aqueous high-shear granulation of veterinary tablet and granule formulations, Aerosol OT Veterinary Grade API—dioctyl sodium sulfosuccinate—functions either as the active ingredient or as an anionic wetting agent in active-loaded systems. When the API is the active ingredient, the blend fraction is calculated from the unit dose and the target tablet weight; a 50 mg dose in a 250 mg finished tablet produces a 20% w/w drug load. At this drug load, direct compression is often unsuitable because the waxy API sticks to punch faces, reduces die-wall lubrication, and generates laminated tablets when compaction pressure exceeds 90 N. Wet granulation is therefore carried out with the API dissolved in the granulating fluid at 25–35 °C before binder addition. A 5–10% w/w API stock solution in purified water is prepared and screened through a 250 µm stainless steel mesh. The anionic sulfonate group lowers the surface tension of the granulating fluid at concentrations below 0.1% w/w; this accelerates wetting of hydrophobic fillers such as cellulose and starch, but above 0.5% w/w it generates persistent foam during mixing and reduces granule density. In a top-drive high-shear granulator with a 100 L bowl, impeller tip speed 8 m/s, and chopper speed 1800 rpm, the endpoint must be controlled by impeller power consumption or torque rather than fixed mixing time because the API shifts the liquid saturation point at which the wet mass becomes cohesive. The wet mass is milled through a 2.0 mm screen and dried in a fluid-bed dryer with inlet air at 50 °C until loss on drying reaches 1.5–2.5% w/w. Dried granules are blended with croscarmellose sodium and screened magnesium stearate, compressed to tablet hardness 70–110 N, and checked for friability below 0.8% w/w by USP <1216>. Dissolution is measured at 37 °C in 900 mL of 0.1 M hydrochloric acid using USP <711> apparatus 2 at 50 rpm. Because docusate sodium precipitates as an insoluble calcium or aluminum salt, granulating fluid prepared from hard water should be softened or replaced with purified water, and uncoated aluminum contact surfaces are avoided. The terminal products are veterinary oral tablets or sachet granules in which the API provides both the intended pharmacological effect and more uniform aqueous dispersion after administration.

Why Does Capsule Fill Weight Variance Increase When API Moisture Exceeds 2.0%?

Capsule manufacture with dosator-type filling equipment exposes the waxy, hygroscopic character of docusate sodium. When the API is blended for two-piece hard gelatin capsules, the target fill moisture is kept below 2.0% w/w because residual water increases adhesion to stainless steel dosator pins, producing weight variation above ±5% on high-speed machines. For a 100 mg docusate sodium dose in a size 0 capsule with a target fill weight of 300 mg, the API fraction is 33.3% w/w, a level at which direct powder filling is rarely robust. The API is first passed through a 500 µm cone mill at low speed to break agglomerates, then blended with microcrystalline cellulose and lactose monohydrate in a twin-shell blender at 10 rpm for 20 min. Colloidal silicon dioxide at 0.25–0.5% w/w is added as a glidant and moisture scavenger. Magnesium stearate is limited to 0.25% w/w and blended for 3–5 min because overlubrication creates a hydrophobic film that slows dissolution of the hydrophilic API. The fill weight is checked every 15 min by automated weight sorting with rejection limits of ±3% around target. Disintegration is tested in 0.1 M hydrochloric acid at 37 °C using USP <701>, and content uniformity is verified with USP <905>. For capsules intended for companion animal dosing, the powder blend may also be filled into sachets or wrapped powders, but the same moisture limit applies because docusate sodium softens and cakes when stored above 60% relative humidity. If the capsule fill exceeds 2.0% w/w moisture, pin adhesion and weight variance become the primary batch-rejection causes before any chemical degradation is detected.

When an Injectable Formulation Must Justify Endotoxin Strategy and Filter Compatibility

If docusate sodium is evaluated as the active ingredient in a parenteral veterinary formulation, the first technical barrier is not water solubility but endotoxin control and subvisible particle load. The API dissolves in water for injection at 20–30 °C; however, heat depyrogenation above 60 °C is generally avoided because the diester structure is susceptible to hydrolysis, and published data for dry-heat depyrogenation of docusate sodium are limited. The endotoxin limit is calculated according to USP <85> using K/M, where K is 5 EU/kg for veterinary parenteral products and M is the maximum dose in mg/kg. For a hypothetical 10 mg/kg maximum dose, the limit becomes 0.5 EU/mg; fill-finish operations must demonstrate that the pre-filter bioburden remains below 10 CFU/100 mL and that the sterilising-grade membrane meets ASTM F838-83 challenge conditions. A 0.22 µm PVDF or PES membrane is preferred; mixed-cellulose esters are unsuitable because membrane wetting agents can interact with the anionic API. The pH is adjusted to 6.0–7.0 with dilute sodium hydroxide or hydrochloric acid, and sodium chloride is used as tonicity agent. Divalent cations, benzalkonium chloride, chlorhexidine, and other cationic preservatives are excluded from the formulation and contact surfaces. Terminal sterilisation is not assumed; if the product is aseptically filtered into single-dose vials, visible particulate inspection follows USP <790>, and subvisible particulate counts are controlled by USP <788>. The injectable solution must also be evaluated for foaming during aseptic filling because the surface-active API reduces surface tension and can entrain air during filling needle discharge. The terminal dosage form is a sterile injectable solution or micellar preparation for veterinary administration, but process validation for this configuration requires formulation-specific data rather than compendial defaults.

Oral drench solutions containing docusate sodium are manufactured as non-sterile aqueous concentrates that must remain clear and free of visible precipitation during shelf life. The API is dissolved in purified water at 20–30 °C using a low-shear axial-flow impeller at 300–500 rpm; concentrations above 20 mg/mL may require 10–20% w/w propylene glycol as a co-solvent to maintain a single liquid phase at 2–8 °C. Sodium benzoate at 0.1% w/w is added as a preservative after the pH is adjusted to 6.0–6.5, because benzoic acid precipitates below pH 4.0. The finished solution is passed through a 10 µm polypropylene filter and filled into high-density polyethylene containers. Preservative efficacy is evaluated with USP <51>; the formulation must meet the acceptance criteria for oral liquids. In-use dilution with hard drinking water is assessed by diluting the product 1:50 v/v in water containing up to 250 mg/L calcium carbonate equivalence; turbidity above 5 NTU after 2 h indicates precipitation of docusate calcium and requires either water softening or a pre-mix sequence in the dosing system. The terminal dosage form is an oral drench for livestock or companion animals, delivered through dosing guns that require viscosity below 300 mPa·s at 20 °C.

Water-Soluble Premix Carrier Selection and Blend Homogeneity

The primary issue in water-soluble premix formulation is not dissolution of docusate sodium but moisture uptake on carriers. Dextrose monohydrate or lactose monohydrate with 0.5–1.0% w/w fumed silica is preferred over sorbitol-based carriers because docusate sodium softens and cakes when residual moisture is present. When the API is the active ingredient, the premix concentration is derived from the intended drinking-water delivery rate; for example, if 1 kg of finished premix is diluted into 1000 L of drinking water and the required product concentration is 1 mg/L, the API content in the premix is 0.1% w/w. For higher delivered concentrations, the premix is recalculated arithmetically from the approved veterinary regimen rather than fixed by a generic formula. The API is dissolved in 40% w/w isopropyl alcohol/water at 35–40 °C and sprayed through a 0.5 mm binary nozzle onto the carrier in a ribbon mixer operating at 20 rpm; the spray rate is limited to 2.0 kg/min per 100 kg carrier to prevent local overwetting and clump formation. After spraying, the premix is dried under vacuum at 40 °C until loss on drying is below 2.0% w/w, then passed through a 710 µm screen. Blend uniformity is confirmed by sampling at least 10 locations; individual docusate sodium assays must fall within 90.0–110.0% of label claim and the relative standard deviation must be ≤5.0%. The finished premix is packed into low-density polyethylene bags with aluminum foil outer liners to limit moisture ingress. At the point of use, the premix must disperse in purified water at 25 °C within 5 min without lumps; a 45 µm screen retains less than 0.1% w/w undissolved material. The terminal product is a water-soluble medicated powder for proportioner or stock-tank administration in poultry, swine, or calves.

Dry powder blends for tablets and sachet filling are exposed to the same plasticising effect of moisture as capsule formulations. Docusate sodium is rarely dry-compressed alone because its waxy consistency produces low tensile strength and sticking to punch faces. In binary or ternary direct compression systems, the API is first pre-blended with lactose monohydrate or dicalcium phosphate dihydrate before adding a disintegrant such as sodium starch glycolate. A 1:1 pre-blend is prepared in a low-shear V-blender at 10 rpm for 10 min; this pre-blend is then diluted to the final active content and mixed for an additional 20 min. Magnesium stearate is added last at 0.25% w/w with a mixing time of 5 min. Compression force is adjusted to produce tablet hardness 50–80 N; above 90 N, laminated tablets may form because docusate sodium reduces interparticulate bonding under high compaction pressure. Ejection force is monitored on a rotary press fitted with 10.0 mm round tooling; sustained ejection force above 200 N indicates insufficient die-wall lubrication and requires either an external lubrication system or a minor increase in magnesium stearate within the 0.25–0.5% w/w range. Finished tablets are packaged in aluminium/PVC cold-form blisters because moisture ingress above 60% relative humidity softens the waxy API and increases tablet sticking after storage.